IRX-2 Biologic Reverses Tumor Immune Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for cancer are ineffective due to tumor-induced immune suppression mechanisms, such as apoptosis of immune cells and dysfunction of dendritic cells, which are not adequately addressed by existing treatments, leading to inadequate anti-tumor responses.
Innovation Solution
Administration of a primary cell-derived biologic, IRX-2, which induces immune production, blocks immune destruction, and promotes the survival of lymphocytes, thereby enhancing both effector generation and survival, and targeting all arms of the immune system to restore immune competence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunotherapies are administered to cancer patients, then immune activation is attempted, but tumor-induced apoptosis of immune cells and immune suppression mechanisms render the therapy ineffective
Solution Approach 1:
The patent applies preliminary anti-action by administering apoptosis-inhibiting agents before or concurrently with immunotherapies to prevent tumor-induced apoptosis of immune cells. This preemptive approach blocks the harmful apoptotic pathways (Fas/FasL, TRAIL, chemotherapy-induced) before they can eliminate the activated immune cells, thereby preserving the immune response and improving immunotherapy effectiveness.
Solution Approach 2:
The patent introduces intermediary substances (apoptosis-inhibiting agents such as NF-κB activators, caspase inhibitors, and Bcl-2 modulators) that mediate between the immunotherapies and the tumor-induced apoptotic mechanisms. These intermediaries protect immune cells from apoptosis while allowing the immunotherapies to function, effectively bridging the gap between immune activation and tumor evasion mechanisms.
2Power
If immunotherapies focus only on activation of anti-tumor immune responses, then immune activation is enhanced, but dysfunction and apoptosis of effector cells create an immune imbalance that cannot be corrected
Solution Approach 1:
The patent extracts the apoptosis-inhibition function from the overall immunotherapy approach by specifically targeting and separating the effector cell survival mechanism from the immune activation process. By using dedicated apoptosis-inhibiting agents that specifically protect effector cells without interfering with immune activation, the patent corrects the immune imbalance caused by excessive effector cell death while maintaining strong immune activation.
3Quantity of substance
If chemotherapy and radiation therapy are used to treat cancer, then tumor cells are killed, but lymphocyte and hematopoietic cells are also damaged due to their sensitivity to these treatments
Solution Approach 1:
The patent converts the harmful effect of chemotherapy and radiation-induced apoptosis into a beneficial outcome by using the same apoptotic pathways targeted by the cancer treatments as therapeutic targets. By administering apoptosis-inhibiting agents that specifically protect lymphocyte and hematopoietic cells from chemotherapy and radiation-induced apoptosis, the patent allows aggressive cancer treatments to be used at full dose while preserving the patient's immune system.
Data Source
AI summary
A method of increasing immunological effect in a patient by administering an effective amount of a primary cell derived biologic to the patient, inducing immune production, blocking immune destruction, and increasing immunological effect in the patient. Methods of treating an immune target, treating a tumor, immune prophylaxis, and preventing tumor escape.